Infantile Severe Myoclonic Epilepsy

Biogen, Stoke Boost Epilepsy Drug’s Blockbuster Potential With Early Seizure Reduction Data

4 weeks ago talkbio0Tagged American Epilepsy Society 2025, Antisense Oligonucleotides, Biogen, blockbuster drug, EMPEROR Phase III trial, Epilepsy, Infantile Severe Myoclonic Epilepsy, Jefferies analysts, natural history controls, SCN1A gene, Seizures, Stoke Therapeutics, Zorevunersen

Biogen; Stoke Therapeutics; zorevunersen; Dravet syndrome; epilepsy; antisense oligonucleotide; seizure reduction; blockbuster drug; EMPEROR Phase III trial; American Epilepsy Society 2025; Jefferies analysts; natural history controls; SCN1A

Biogen and Stoke Therapeutics Partner on Promising Dravet Syndrome Treatment

11 months ago talkbio0Tagged Antisense, Biogen, Drug Development, Epilepsy, Infantile Severe Myoclonic Epilepsy, Infrequent, Oligonucleotides, pharmaceutical partnership, Stoke, Zorevunersen

Biogen, Stoke Therapeutics, zorevunersen, Dravet syndrome, antisense oligonucleotide, rare epilepsy, drug development, pharmaceutical partnership

Stoke Therapeutics Announces Global Phase 3 EMPEROR Study Design for Zorevunersen in Dravet Syndrome

11 months ago talkbio0Tagged Clinical Research, Cognitive Improvement, EMPEROR, Infantile Severe Myoclonic Epilepsy, Phase 3 trial, regulatory, Seizures, Zorevunersen

Dravet syndrome, zorevunersen, Phase 3 trial, EMPEROR study, seizure reduction, cognitive improvement, regulatory alignment

Ovid Halts Preclinical Work and IV Seizure Program Following Soticlestat’s Phase 3 Setbacks

1 year ago talkbio0Tagged Dosage Forms, Infantile Severe Myoclonic Epilepsy, Lennox-Gastaut syndrome, Phase 3 trials, Preclinical, soticlestat, Takeda

Ovid Therapeutics, soticlestat, Phase 3 trials, Dravet syndrome, Lennox-Gastaut syndrome, preclinical work, IV seizure program, Takeda Pharmaceutical

Stoke Therapeutics Advances Dravet Syndrome Drug to Phase III Trials After FDA Lifts Partial Clinical Hold

1 year ago talkbio0Tagged Activator, Infantile Severe Myoclonic Epilepsy, orphan drug designation, pediatric disease designation, Phase 3 Clinical Trials, SCN1A gene, Stoke, United States Food and Drug Administration, Zorevunersen

Stoke Therapeutics, Dravet syndrome, Phase III trials, FDA, zorevunersen, SCN1A activator, orphan drug designation, rare pediatric disease designation

Takeda’s Soticlestat Misses Main Goal in Two Pivotal Epilepsy Studies

2 years ago talkbio0Tagged Epilepsy, Infantile Severe Myoclonic Epilepsy, Lennox-Gastaut syndrome, Phase 3 trials, Seizures, soticlestat, Takeda, With frequency

Soticlestat, Takeda, Epilepsy, Dravet Syndrome, Lennox-Gastaut Syndrome, Phase 3 Trials, Seizure Frequency

Harmony Pharmaceuticals Expands into Rare Genetic Epilepsies with Acquisition of Epygenix Therapeutics

2 years ago talkbio0Tagged Acquisition (action), CDK-like kinase inhibitors, Collaboration, development aspects, Epygenix, genetic epilepsies, Harmony Pharmaceuticals, Infantile Severe Myoclonic Epilepsy, Mutation, research

Harmony Pharmaceuticals, Epygenix Therapeutics, rare genetic epilepsies, acquisition, treatment, research, development, collaboration, genetic mutations, Dravet syndrome, CDK-like kinase inhibitors

Groundbreaking Data Revealed for Genetic Epilepsy Drug STK-001 by Stoke Therapeutics, Exhilarating Investors

2 years ago talkbio0Tagged Antisense Oligonucleotides, Genetic Epilepsy Drug, Infantile Severe Myoclonic Epilepsy, investor, Level of interest, Positive Clinical Trial, Seizures, STK-001, Stoke

Stoke Therapeutics, STK-001, Genetic Epilepsy Drug, Dravet Syndrome, Antisense Oligonucleotide, Seizure Reduction, Positive Clinical Trial Data, Investor Enthusiasm